SARS-CoV-2 spike S2-specific neutralizing antibodies
CJ Li, SC Chang - Emerging Microbes & Infections, 2023 - Taylor & Francis
Since the onset of the coronavirus disease 2019 (COVID-19), numerous neutralizing
antibodies (NAbs) against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) …
antibodies (NAbs) against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) …
Pre-exposure prophylaxis with tixagevimab and cilgavimab (Evusheld) for COVID-19 among 1112 severely immunocompromised patients
Y Nguyen, A Flahault, N Chavarot, C Melenotte… - Clinical Microbiology …, 2022 - Elsevier
Objective Immunocompromised patients have an increased risk of a severe form of COVID-
19. The clinical efficacy of the tixagevimab/cilgavimab monoclonal antibody combination as …
19. The clinical efficacy of the tixagevimab/cilgavimab monoclonal antibody combination as …
[HTML][HTML] Global trends in COVID-19
The pandemic COVID-19 is certainly one of the most severe infectious diseases in human
history. In the last 2 years, the COVID-19 pandemic has caused over 418.6 million confirmed …
history. In the last 2 years, the COVID-19 pandemic has caused over 418.6 million confirmed …
Targeted SARS-CoV-2 treatment is associated with decreased mortality in immunocompromised patients with COVID-19
E Lafont, H Pere, D Lebeaux… - Journal of …, 2022 - academic.oup.com
Background Little is known about targeted (antiviral or monoclonal antibody) anti-SARS-
CoV-2 treatment in immunocompromised patients with COVID-19. Objectives To assess the …
CoV-2 treatment in immunocompromised patients with COVID-19. Objectives To assess the …
Issues regarding COVID-19 in kidney transplantation in the ERA of the Omicron variant: a commentary by the ERA Descartes Working Group
I Gandolfini, M Crespo, R Hellemans… - Nephrology Dialysis …, 2022 - academic.oup.com
The Omicron variant, which has become the dominant strain of severe acute respiratory
syndrome coronavirus 2 (SARS-CoV-2) worldwide, brings new challenges to preventing and …
syndrome coronavirus 2 (SARS-CoV-2) worldwide, brings new challenges to preventing and …
Safety and efficacy of tixagevimab/cilgavimab for pre-exposure prophylaxis in kidney transplant recipients: a multicenter retrospective cohort study
S Simone, V Pronzo, F Pesce, DF Bavaro, B Infante… - Journal of …, 2024 - Springer
Background Immunocompromised patients show an impaired vaccine response and remain
at high risk of severe COVID-19, despite vaccination. Neutralizing monoclonal antibodies …
at high risk of severe COVID-19, despite vaccination. Neutralizing monoclonal antibodies …
Development and external validation of the DOAT and DOATS scores: simple decision support tools to identify disease progression among nonelderly patients with …
Y Shibata, K Omae, H Minemura, Y Suzuki… - BMC Pulmonary …, 2023 - Springer
Background During the fifth wave of the coronavirus disease 2019 (COVID-19) pandemic in
Japan, which took place between June and September 2021, a significant number of COVID …
Japan, which took place between June and September 2021, a significant number of COVID …
[PDF][PDF] Infectious Medicine
CM Zhou, R Qi, XR Qin, LZ Fang, HJ Han, XY Lei… - 2021 - researchgate.net
abstract The pandemic COVID-19 is certainly one of the most severe infectious diseases in
human history. In the last 2 years, the COVID-19 pandemic has caused over 418.6 million …
human history. In the last 2 years, the COVID-19 pandemic has caused over 418.6 million …